药明生物表示“稳步实现”2025财年收入和利润双双增长

Core Viewpoint - WuXi Biologics is steadily achieving its fiscal year 2025 goals with both revenue and profit growth, supported by its research services, drug development, and manufacturing businesses [1] Group 1: Business Performance - The company is expected to continue its growth momentum into fiscal year 2026, driven by strong performance in research services and drug development [1] - The research services segment is maintaining its robust momentum from 2024 into 2025, with accelerated collaboration on CD3 TCE molecules [1] Group 2: Financial Milestones - The potential milestone payments from collaboration projects in 2025 could exceed $4 billion [1]